HealthInvest Partners AB Has $2.82 Million Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

HealthInvest Partners AB increased its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 92.8% in the 4th quarter, Holdings Channel reports. The firm owned 103,032 shares of the company’s stock after buying an additional 49,600 shares during the quarter. BridgeBio Pharma comprises approximately 1.3% of HealthInvest Partners AB’s investment portfolio, making the stock its 23rd biggest position. HealthInvest Partners AB’s holdings in BridgeBio Pharma were worth $2,815,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of BBIO. Janus Henderson Group PLC raised its stake in shares of BridgeBio Pharma by 11.7% in the 3rd quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company’s stock valued at $122,658,000 after buying an additional 505,481 shares in the last quarter. Emerald Advisers LLC raised its position in BridgeBio Pharma by 65.6% in the third quarter. Emerald Advisers LLC now owns 1,103,508 shares of the company’s stock worth $28,095,000 after purchasing an additional 437,164 shares in the last quarter. First Turn Management LLC acquired a new position in BridgeBio Pharma in the third quarter worth about $10,178,000. Emerald Mutual Fund Advisers Trust lifted its stake in BridgeBio Pharma by 50.8% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 751,355 shares of the company’s stock worth $19,129,000 after purchasing an additional 253,101 shares during the period. Finally, Erste Asset Management GmbH acquired a new stake in BridgeBio Pharma during the third quarter valued at approximately $3,497,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Price Performance

Shares of BridgeBio Pharma stock opened at $36.85 on Monday. The firm has a market cap of $6.96 billion, a price-to-earnings ratio of -12.93 and a beta of 1.07. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47. The stock’s 50-day moving average is $31.90 and its 200-day moving average is $27.98.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analysts’ expectations of $4.04 million. On average, equities analysts expect that BridgeBio Pharma, Inc. will post -3.66 EPS for the current year.

Insider Buying and Selling

In other BridgeBio Pharma news, CEO Neil Kumar sold 31,543 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $36.14, for a total transaction of $1,139,964.02. Following the transaction, the chief executive officer now owns 211,718 shares of the company’s stock, valued at $7,651,488.52. The trade was a 12.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $34.90, for a total value of $106,989,998.40. Following the completion of the sale, the insider now directly owns 22,055,375 shares of the company’s stock, valued at approximately $769,732,587.50. The trade was a 12.20 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,496,239 shares of company stock worth $122,612,036. 24.66% of the stock is owned by insiders.

Analyst Ratings Changes

BBIO has been the subject of a number of recent research reports. Citigroup increased their target price on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday. Scotiabank increased their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Friday. Cantor Fitzgerald restated an “overweight” rating and issued a $95.00 target price on shares of BridgeBio Pharma in a research note on Friday. Evercore ISI increased their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Finally, Bank of America lifted their price target on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $51.67.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.